Literature DB >> 1123553

Assay of therapeutic doses of methotrexate in body fluids of patients with psoriasis.

W C Noble, P M White, H Baker.   

Abstract

A microbiologic technique for the assay of methotrexate (MTX) in urine, serum, erythrocytes, feces, and skin is described. The accuracy of the method equals that of routine microbiologic assays of folic acid. Important differences in serum MTX levels in psoriatic patients during the 24 hours after standardized intravenous and intramuscular administration were demonstrated. Repeated intravenous doses tended to be cleared from the blood univormly. After oral doses many patients achieved peak serum levels within 2 hr. with fall of level by 4 hr. Others achieved lower levels and responded less well clinically. Persistence of high serum levels at 24 and 48 hr did not confer obvious clinical benefit or necessarily give rise to by renal function when the creatinine clearance was greater than 50 ml/min. However, impaired renal function was clearly correlated with slow clearance. Routine measurement of MTX blood levels is of value in patients with suspected malabsorption or partial renal failure.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1123553     DOI: 10.1111/1523-1747.ep12510255

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  5 in total

1.  A microbiological assay for the measurement of methotrexate in biological fluids.

Authors:  G C Icke; R E Davis; J Thom
Journal:  J Clin Pathol       Date:  1983-10       Impact factor: 3.411

2.  The bioavailability of oral intermediate-dose methotrexate. Effect of dose subdivision, formulation, and timing in the chemotherapy cycle.

Authors:  V J Harvey; M L Slevin; R C Woollard; A Johnston; M J Barnett; P F Wrigley; P Turner
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

Review 3.  Pneumocystis carinii pneumonia complicating low dose methotrexate treatment for rheumatoid arthritis.

Authors:  A Wollner; J Mohle-Boetani; R E Lambert; J L Perruquet; T A Raffin; J L McGuire
Journal:  Thorax       Date:  1991-03       Impact factor: 9.139

4.  Clinical pharmacology of intermediate-dose oral methotrexate.

Authors:  D K Smith; G A Omura; F Ostroy
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

5.  Serum profiles of methotrexate after its administration in children with acute lymphoblastic leukaemia.

Authors:  C R Pinkerton; S G Welshman; J M Bridges
Journal:  Br J Cancer       Date:  1982-02       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.